Intravenous vernakalant rapidly converted 82% of recent-onset atrial fibrillation episodes to sinus rhythm within minutes of administration in the emergency department.
Observational (n=328)
No
Does intravenous vernakalant safely and effectively convert recent-onset atrial fibrillation to sinus rhythm in emergency department patients?
Intravenous vernakalant is highly effective for rapidly terminating recent-onset atrial fibrillation in the emergency department, achieving an 82% conversion rate with a generally favorable safety profile.
Background.Early conversion of recent-onset atrial fibrillation (AF) is of clinical value.Vernakalant is an atrial-selective, rapid-acting, antiarrhythmic drug.We report a large cohort of consecutive patients receiving vernakalant for the conversion of AF and review the clinical trials reporting on its safety and efficacy.Conclusions.In an emergency department, intravenous vernakalant was highly effective for terminating recent-onset AF, rapidly converting 82% of AF episodes within minutes of drug administration.
Heller et al. (Sun,) conducted a observational in recent-onset atrial fibrillation (n=328). Vernakalant vs. placebo or other antiarrhythmic drugs was evaluated on conversion to sinus rhythm. Intravenous vernakalant rapidly converted 82% of recent-onset atrial fibrillation episodes to sinus rhythm within minutes of administration in the emergency department.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: